Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Research Output

Filter
Comment/debate
2020

Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Brewer, M. R., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & 2 others, Hanker, A. B. & Arteaga, C. L., Feb 10 2020, In : Cancer Cell. 37, 2, p. 258-259 2 p.

Research output: Contribution to journalComment/debate

Open Access
2019
Open Access

Correction: Pik3ca c2 domain deletions hyperactivate phosphoinositide 3-kinase (pi3k), generate oncogene dependence, and are exquisitely sensitive to pi3ka inhibitors(Clin Cancer Res (2018) 24 (1426–35)DOI: 10.1158/1078-0432.CCR-17-2141)

Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Open Access

Correction: 18 F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)

Wang, Y., Ayres, K. L., Goldman, D. A., Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E., Fredrickson, J., Arteaga, C. L., Baselga, J., Manning, H. C., Mahmood, U. & Ulaner, G. A., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and Notch-dependent cancer stem cell population (Cancer Research (2016) 76 (440–452) DOI: 10.1158/0008-5472.CAN-15-1640-T)

Bhola, N. E., Jansen, V. M., Koch, J. P., Li, H., Formisano, L., Williams, J. A., Grandis, J. R. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer (Cancer Research (2017) 77 (3280–3292) DOI: 10.1158/0008-5472.CAN-16-2808)

Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sánchez, V., Rexer, B. N., Sanders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Feb 15 2019, In : Cancer research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., Sanchez, V., Sanders, M. E., Cook, R. S., Pilkinton, M. A., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., Doimi, F. D. & 5 others, Gomez, H., Ryzhov, S. V., Darcy, P. K., Arteaga, C. L. & Balko, J. M., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
3 Scopus citations

Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J. J., Perez-Fidalgo, A., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V. & 2 others, Ruiz-Simon, A. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2(Clin Cancer Res. (2017) 23:15 (4323-4334) DOI: 10.1158/1078-0432.CCR-16-2287)

Hanker, A. B., Garrett, J. T., Valeria Estrada, M., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S. & 6 others, Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: Association of FGFR1 with ERA maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER þ breast cancer (Clinical Cancer Research (2019)23 (6138–6150) Doi:10.1158/1078-0432.CCR-17-1232)

Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Angel, L. G. Z., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., Lu, Y., Balko, J. M., Deas, O., Cairo, S., Judde, J. G., Mayer, I. A., Sanders, M., Dugger, T. C., Bianco, R., Stricker, T. & 1 others, Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer (Cancer Research (2015) 75 (405–414) DOI: 10.1158/0008-5472.CAN-14-2475)

Bhola, N. E., Jansen, V. M., Bafna, S., Giltnane, J. M., Balko, J. M., Estrada, M. V., Meszoely, I., Mayer, I., Abramson, V., Ye, F., Sanders, M., Dugger, T. C., Allen, E. V. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of oncology : official journal of the European Society for Medical Oncology (2018) 29 7 (1541-1547) PII: S0923-7534(20)32578-3)

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C. & 1 others, O'Shaughnessy, J., Nov 1 2019, In : Annals of oncology : official journal of the European Society for Medical Oncology. 30, 11, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Erratum: Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer (eLife (2016) 5 PII: e44851)

Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K. & 26 others, Moon, M., Prudente, R., Bischoff, E., Lee, K. J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C. & Hager, J. H., Jan 7 2019, In : eLife. 8

Research output: Contribution to journalComment/debate

Erratum for the research article: Genomic proling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (Science Translational Medicine DOI: 10.1126/scitranslmed.aai7993)

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V., Ericsson, P. G., Kuba, M. G., Sanders, M. E., Mu, X. J., Van Allen, E. M., Wagle, N., Mayer, I. A., Abramson, V., Gόmez, H., Rizzo, M., Toy, W. & 15 others, Chandarlapaty, S., Mayer, E. L., Christiansen, J., Murphy, D., Fitzgerald, K., Wang, K., Ross, J. S., Miller, V. A., Stephens, P. J., Yelensky, R., Garraway, L., Shyr, Y., Meszoely, I., Balko, J. M. & Arteaga, C. L., Feb 13 2019, In : Science Translational Medicine. 11, 479, eaaw7620.

Research output: Contribution to journalComment/debate

Erratum for The research article: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation (Science Translational Medicine DOI: 10.1126/scitranslmed.aal4682)

Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M., Goel, S., Qi, X., Shankaraiah, R., Cao, Z. A., Ramjiawan, R. R., Bezwada, D., Patel, B., Song, Y., Costa, C., Naxerova, K., Wong, C. S. F., Kloepper, J., Das, R., Tam, A., Tanboon, J. & 13 others, Duda, D. G., Miller, C. R., Siegel, M. B., Anders, C. K., Sanders, M., Estrada, M. V., Schlegel, R., Arteaga, C. L., Brachtel, E., Huang, A., Fukumura, D., Engelman, J. A. & Jain, R. K., Jan 30 2019, In : Science Translational Medicine. 11, 477, aaw6935.

Research output: Contribution to journalComment/debate

Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

Unni, N. & Arteaga, C. L., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journalComment/debate

1 Scopus citations
2018

Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Garrett, J. T., Chakrabarty, A. & Arteaga, C. L., Aug 17 2018, In : Oncotarget. 9, 64, p. 32400 1 p.

Research output: Contribution to journalComment/debate

Correction: Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer (Cancer Research (2017) 77 (2488-2499) DOI: 10.1158/0008-5472)

Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K. M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., Ericsson, P. G., Sanders, M. E., Pohlmann, P. R., Pishvaian, M. J., Riddle, D. A., Dugger, T. C., Wei, W., Knudsen, E. S. & Arteaga, C. L., Feb 15 2018, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

2015

Surviving surveillance

Sweetenham, J. W., Jan 1 2015, In : ONCOLOGY (United States). 29, 4

Research output: Contribution to journalComment/debate

2013

Mouse models and anti-HER2 therapies

Hanker, A. B., Cook, R. S. & Arteaga, C. L., Nov 2013, In : Oncotarget. 4, 11, p. 1866-1867 2 p.

Research output: Contribution to journalComment/debate

Open Access
1 Scopus citations
2011

Dead-box or black-box: Is DDX1 a potential biomarker in breast cancer?

Balko, J. M. & Arteaga, C. L., May 1 2011, In : Breast Cancer Research and Treatment. 127, 1, p. 65-67 3 p.

Research output: Contribution to journalComment/debate

10 Scopus citations

Early initial therapy of advanced follicular lymphoma: The need for vigilance

Sweetenham, J. W. & Freedman, A. S., Mar 1 2011, In : Leukemia and Lymphoma. 52, 3, p. 355-357 3 p.

Research output: Contribution to journalComment/debate

Open Access

"Pet Negativity" -The new goal of cytoreductive therapy in Hodgkin's lymphoma?

Sweetenham, J. W., Nov 1 2011, In : Biology of Blood and Marrow Transplantation. 17, 11, p. 1569-1570 2 p.

Research output: Contribution to journalComment/debate

Open Access
2 Scopus citations

Progressive transformation of germinal centers and Hodgkin lymphoma: More insights but maybe more confusion?

Sweetenham, J. W. & Polliack, A., Nov 1 2011, In : Leukemia and Lymphoma. 52, 11, p. 2041-2042 2 p.

Research output: Contribution to journalComment/debate

2010

Does lapatinib work against HER2-negative breast cancers?

Mayer, I. A. & Arteaga, C. L., Mar 1 2010, In : Clinical Cancer Research. 16, 5, p. 1355-1357 3 p.

Research output: Contribution to journalComment/debate

14 Scopus citations

Intensive therapies for mantle cell lymphoma: Time for a disease-specific approach?

Smith, S. D. & Sweetenham, J. W., Mar 2010, In : Leukemia and Lymphoma. 51, 3, p. 357-359 3 p.

Research output: Contribution to journalComment/debate

Open Access

Ocular adnexal mucosa-associated lymphoid tissue lymphomas: More clues but still a puzzle

Tadmor, T., Polliack, A. & Sweetenham, J., Nov 1 2010, In : Leukemia and Lymphoma. 51, 11, p. 1951-1953 3 p.

Research output: Contribution to journalComment/debate

3 Scopus citations

Posttransplant lymphoproliferative disorder after living donor liver transplant: Are we improving incidence and outcome?

Tadmor, T., Polliack, A. & Sweetenham, J., Aug 1 2010, In : Leukemia and Lymphoma. 51, 8, p. 1393-1394 2 p.

Research output: Contribution to journalComment/debate

1 Scopus citations
2009

Inhibition of PI3K and MEK: It is all about combinations and biomarkers

Rexer, B. N., Ghosh, R. & Arteaga, C. L., Jul 15 2009, In : Clinical Cancer Research. 15, 14, p. 4518-4520 3 p.

Research output: Contribution to journalComment/debate

33 Scopus citations
2008
1 Scopus citations
2006

The Armitage/Bierman/Bociek et al article reviewed

Sweetenham, J. W., Dec 1 2006, In : ONCOLOGY. 20, 3, p. 242-244 3 p.

Research output: Contribution to journalComment/debate

2004

Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?

Arteaga, C. L. & Baselga, J., Jun 2004, In : Cancer Cell. 5, 6, p. 525-531 7 p.

Research output: Contribution to journalComment/debate

85 Scopus citations
2001

The real world costs of Hodgkin's disease

Sweetenham, J., Dec 1 2001, In : Oncology Spectrums. 2, 10, 1 p.

Research output: Contribution to journalComment/debate

1998

Erratum: Growth retardation and tumour inhibition by BRCA1 (Nature Genetics (1996) 12 (pp. 298-302))

Holt, J. T., Thompson, M. E., Szabo, C., Robinson-Benion, C., Arteaga, C. L., King, M. C. & Jensen, R. A., Jan 1 1998, In : Nature genetics. 19, 1, 1 p.

Research output: Contribution to journalComment/debate

5 Scopus citations